Korsana Biosciences, Inc. (KRSA) shareholders
Close on Nov 17, 2026Market cap $152.14MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Tomas Kiselak Joint filing with Fairmount Funds Management LLC (19.99%), Peter Evan Harwin (19.99%) and 1 more | 9,106,420 | 19.99% | 13D (active) | Sep 8, 2026 |
| Nimish Shah Joint filing with Venrock Healthcare Capital Partners III, L.P. (9.90%), VHCP Co-Investment Holdings III, LLC (9.90%) and 6 more | 4,552,277 | 9.90% | 13D (active) | Sep 8, 2026 |
| General Atlantic, L.P. Joint filing with General Atlantic Partners 100, L.P. (6.80%), GAP Coinvestments III, LLC (6.80%) and 14 more | 3,201,131 | 6.80% | 13G (passive) | Sep 8, 2026 |
| Abigail P. Johnson Joint filing with FMR LLC (6.90%) | 3,144,797 | 6.90% | 13G (passive) amendment | Sep 30, 2026 |
| Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. | 2,775,788 | 6.10% | 13G (passive) | Sep 9, 2026 |
| JPMorgan Chase & Co. | 2,687,914 | 5.90% | 13G (passive) | Sep 30, 2026 |
| Peter M. Hecht | 910,240 | 19.40% | 13D (active) amendment | Jul 16, 2026 |
| Bam Gp LLC Joint filing with Balyasny Asset Management L.P. (7.33%), Balyasny Asset Management Holdings LP (7.33%) and 2 more | 317,511 | 7.33% | 13G (passive) | Jun 30, 2026 |
| ADAR1 Capital Management, LLC Joint filing with Daniel Schneeberger (7.00%) | 298,757 | 7.00% | 13G (passive) | Jun 30, 2026 |
| J. Wood Capital Advisors LLC Joint filing with Jason Wood (5.40%) | 181,818 | 5.40% | 13G (passive) | Mar 25, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of KRSA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Kalehua Capital Management LLC | 471,814 | 10.08% | $11.20M | New | 3.57% |
| FMR LLC | 92,793 | 1.98% | $2.20M | +92,116 | 0.00% |
| Balyasny Asset Management L.P. | 45,359 | 0.97% | $1.08M | New | 0.00% |
| ADAR1 Capital Management, LLC | 42,680 | 0.91% | $1.01M | New | 0.05% |
| Braidwell LP | 22,413 | 0.48% | $531.86K | New | 0.02% |
| Citadel Advisors LLC | 8,542 | 0.18% | $202.71K | +5,933 | 0.00% |
| Geode Capital Management, LLC | 6,550 | 0.14% | $155.47K | −5,528 | 0.00% |
| Vanguard Capital Management LLC | 4,416 | 0.09% | $104.80K | +2,111 | 0.00% |
| Rangeley Capital, LLC | 3,473 | 0.07% | $82.41K | New | 0.08% |
| Hrt Financial LP | 3,151 | 0.07% | $74.00K | New | 0.00% |
| BlackRock, Inc. | 2,400 | 0.05% | $56.94K | – | 0.00% |
| Dimensional Fund Advisors LP | 1,675 | 0.04% | $39.75K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 1,050 | 0.02% | $24.93K | – | 0.00% |
| UBS Group AG | 448 | 0.01% | $10.63K | −37 | 0.00% |
| Tower Research Capital LLC (TRC) | 264 | 0.01% | $6.27K | New | 0.00% |
| Group One Trading, L.P. | 27 | 0.00% | $651 | – | 0.00% |
| Osaic Holdings, Inc. | 19 | 0.00% | $440 | – | 0.00% |
| Activest Wealth Management | 14 | 0.00% | $339 | – | 0.00% |
| Barclays PLC | 12 | 0.00% | $295 | New | 0.00% |
| WHI TRUST Co LLC | 10 | 0.00% | $244 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 21 | 1M | 15.1% | 9 / 3 | 2 / 5 | 1M | 0M |
| Q1 2026 | 17 | 0M | 0.5% | 5 / 2 | 1 / 6 | 0M | 0M |
| Q4 2025 | 19 | 0M | 0.9% | 4 / 5 | 3 / 2 | 0M | 0M |
| Q3 2025 | 17 | 0M | 0.8% | 3 / 2 | 3 / 3 | 0M | 0M |
| Q2 2025 | 17 | 0M | 1.1% | 1 / 3 | 4 / 2 | 0M | 0M |
| Q1 2025 | 18 | 0M | 1.1% | 0 / 2 | 2 / 1 | 0M | 0M |
| Q4 2024 | 19 | 0M | 1.2% | 6 / 2 | 3 / 2 | 0M | 0M |
| Q3 2024 | 15 | 0M | 3.2% | 2 / 1 | 4 / 3 | 0M | 0M |
| Q2 2024 | 17 | 0M | 3.2% | 3 / 4 | 3 / 1 | 0M | 0M |
| Q1 2024 | 15 | 0M | 3.3% | 1 / 5 | 1 / 1 | 0M | 0M |
| Q4 2023 | 15 | 0M | 3.3% | 0 / 5 | 4 / 2 | 0M | 0M |
| Q3 2023 | 17 | 0M | 3.3% | 2 / 3 | 4 / 3 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jonathan Violin | See Remarks, Director | 207,400 | 4.43% | Sep 10, 2026 |
| Regina Margaret Graul | See Remarks, Director | 156,152 | 3.34% | Aug 18, 2026 |
| Matthew James Leoni | Chief Medical Officer | – | – | Sep 10, 2026 |
| Mark J. Vignola | Chief Financial Officer | – | – | Sep 10, 2026 |
| Rhonda M. Chicko | Chief Financial Officer | 25,018 | 0.53% | Aug 18, 2026 |
| Michelle Patricia Pernice | Director | – | – | Sep 10, 2026 |
| Nimish P. Shah | Director | 4,549,585 | 97.19% | Sep 10, 2026 |
| Andrew Gottesdiener | Director | – | – | Sep 10, 2026 |
| Healthcare Co-Invest VI L.P. Fairmount | Director, 10% owner | – | – | Sep 10, 2026 |
| Healthcare Fund II L.P. Fairmount | Director, 10% owner | 9,103,729 | 194.47% | Sep 10, 2026 |
| Tomas Kiselak | Director, 10% owner | – | – | Sep 10, 2026 |
| Funds Management LLC Fairmount | Director, 10% owner | – | – | Sep 10, 2026 |
| Peter Evan Harwin | Director, 10% owner | – | – | Sep 10, 2026 |
| Heidi Henson | Director | – | – | Sep 10, 2026 |
| Peter M. Hecht | Director, 10% owner | 910,312 | 19.45% | Jul 20, 2026 |
| Michael J. Higgins | Director | 30,740 | 0.66% | Mar 27, 2025 |
| Path Capital LP Slate | 10% owner | 6,196,063 | 132.36% | Nov 25, 2024 |
| David Gerald Greenspan | 10% owner | 0 | – | Nov 25, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Rhonda M. Chicko Chief Financial Officer | Aug 14, 2026 | Option exercise | +25,000 | $2.36 | $59.00K | 25,018 |
| Regina Margaret Graul See Remarks, Director | Aug 14, 2026 | Option exercise | +55,849 | $3.30 | $184.30K | 156,152 |
| Regina Margaret Graul See Remarks, Director | Aug 14, 2026 | Tax withholding | −48,629 | $3.79 | $184.30K | 107,523 |
| Peter M. Hecht Director, 10% owner | Jul 16, 2026 | Conversion | +351,037 | – | – | 910,240 |
| Michael J. Higgins Director | Mar 25, 2025 | Award | +9,090 | $2.75 | $25.00K | 30,740 |
| Peter M. Hecht Director, 10% owner | Mar 25, 2025 | Award | +181,818 | $2.75 | $500.00K | 559,203 |
| David Gerald Greenspan 10% owner | Nov 21, 2024 | Sale | −357,880 | $1.55 | $554.71K | 0 |
| Regina Margaret Graul President | Jan 1, 2024 | Award | +50,000 | – | – | 100,303 |
| Peter M. Hecht Director, 10% owner | Jan 1, 2024 | Award | +15,000 | – | – | 377,385 |
| Peter M. Hecht Director, 10% owner | Dec 1, 2023 | Award | +15,000 | – | – | 362,385 |
| Terrance McGuire Director | Nov 30, 2023 | Award | +5,000 | – | – | 5,552 |
| Peter M. Hecht Director, 10% owner | Nov 30, 2023 | Award | +20,000 | – | – | 347,385 |
| Errol B. Desouza Director | Nov 30, 2023 | Award | +20,000 | – | – | 50,000 |
| Errol B. Desouza Director | Nov 30, 2023 | Award | +30,000 | – | – | 30,000 |
| Steven Hyman Director | Nov 30, 2023 | Award | +20,000 | – | – | 20,000 |
| Terrance McGuire Director | Aug 9, 2023 | Sale | −8 | $3.40 | $27 | 0 |
| Peter M. Hecht Chief Executive Officer, Director, 10% owner | May 19, 2023 | Award | +225,000 | $8.68 | $1.95M | 327,385 |
| Peter M. Hecht Chief Executive Officer, Director | Jun 3, 2021 | Buy | +823,170 | $3.28 | $2.70M | 2,047,698 |
| David Gerald Greenspan 10% owner | Jun 3, 2021 | Buy | +961,538 | $3.12 | $3.00M | 7,157,601 |
| Terrance McGuire Director | Jun 3, 2021 | Buy | +3,322 | $3.12 | $10.36K | 24,957 |
| Terrance McGuire Director | Jun 3, 2021 | Buy | +92,831 | $3.12 | $289.63K | 697,313 |
| Peter M. Hecht Chief Executive Officer, Director | May 6, 2021 | Buy | +302,000 | $2.43 | $733.86K | 1,224,528 |
| Peter M. Hecht Chief Executive Officer, Director | May 5, 2021 | Buy | +398,001 | $2.53 | $1.01M | 922,528 |
| Peter M. Hecht Chief Executive Officer, Director | May 4, 2021 | Buy | +300,000 | $2.29 | $687.00K | 524,527 |
| Christopher I. Wright Chief Medical Officer | Feb 25, 2021 | Sale(10b5-1 plan) | −2,637 | $3.99 | $10.52K | 42,728 |
| Anjeza Gjino Chief Financial Officer | Feb 25, 2021 | Sale(10b5-1 plan) | −1,824 | $4.00 | $7.30K | 31,599 |
| Mark G. Currie President and CSO | Dec 28, 2020 | Sale | −20,107 | $3.01 | $60.52K | 251,648 |
| Andreas Busch Chief Innovation Officer | Nov 9, 2020 | Buy | +125,000 | $2.53 | $316.25K | 254,704 |
| William Huyett Chief Financial Officer | Nov 6, 2020 | Sale(10b5-1 plan) | −3,827 | $2.52 | $9.64K | 67,590 |
| William Huyett Chief Financial Officer | Feb 21, 2020 | Sale(10b5-1 plan) | −3,559 | $5.12 | $18.22K | 71,417 |
| Mark G. Currie President | Dec 30, 2019 | Sale | −25,000 | $2.48 | $62.00K | 271,755 |
| Mark G. Currie President | Dec 27, 2019 | Sale | −25,000 | $2.55 | $63.75K | 296,755 |
| Andreas Busch Chief Innovation Officer | Nov 15, 2019 | Buy | +125,000 | $1.82 | $227.50K | 125,000 |
| William Huyett Chief Financial Officer | Nov 8, 2019 | Sale(10b5-1 plan) | −3,922 | $2.05 | $8.04K | 74,976 |
| Peter M. Hecht Chief Executive Officer, Director | Jul 10, 2019 | Option exercise | +2,000 | $6.04 | $12.08K | 225,192 |
| Amy W. Schulman Director | Apr 8, 2019 | Buy | +604,482 | $16.00 | $9.67M | 604,482 |
| Amy W. Schulman Director | Apr 8, 2019 | Buy | +21,635 | $16.00 | $346.16K | 21,635 |
| Terrance McGuire Director | Apr 8, 2019 | Buy | +21,635 | $16.00 | $346.16K | 21,635 |
| Terrance McGuire Director | Apr 8, 2019 | Buy | +604,482 | $16.00 | $9.67M | 604,482 |
| Mark G. Currie President | Apr 2, 2019 | Buy | +270,107 | $14.81 | $4.00M | 321,755 |
| Peter M. Hecht Chief Executive Officer, Director | Apr 1, 2019 | Award | +221,736 | – | – | 221,736 |
| William Huyett Chief Financial Officer | Apr 1, 2019 | Award | +38,320 | – | – | 38,320 |
| William Huyett Chief Financial Officer | Apr 1, 2019 | Award | +39,172 | – | – | 78,898 |
| George H. Conrades Director | Apr 1, 2019 | Award | +2,421 | – | – | 4,334 |
| Marsha Fanucci Director | Apr 1, 2019 | Award | +13,671 | – | – | 13,671 |
| Marsha Fanucci Director | Apr 1, 2019 | Award | +3,279 | – | – | 16,950 |
| Mark G. Currie President | Apr 1, 2019 | Award | +51,648 | – | – | 51,648 |
| William Huyett Chief Financial Officer | Apr 1, 2019 | Award | +39,179 | – | – | 78,912 |
| William Huyett Chief Financial Officer | Apr 1, 2019 | Award | +38,327 | – | – | 38,327 |
| Kevin Churchwell Director | Apr 1, 2019 | Award | +2,421 | – | – | 2,421 |
| Amy W. Schulman Director | Apr 1, 2019 | Award | +3,279 | – | – | 7,508 |
| Amy W. Schulman Director | Apr 1, 2019 | Award | +4,229 | – | – | 4,229 |
| Ole Isacson Director | Apr 1, 2019 | Award | +2,421 | – | – | 2,421 |
| George H. Conrades Director | Apr 1, 2019 | Award | +2,421 | – | – | 2,421 |
| Stephanie Lovell Director | Apr 1, 2019 | Award | +2,421 | – | – | 2,421 |
| Terrance McGuire Director | Apr 1, 2019 | Award | +7,768 | – | – | 7,768 |
| Terrance McGuire Director | Apr 1, 2019 | Award | +3,279 | – | – | 3,279 |
| Terrance McGuire Director | Apr 1, 2019 | Award | +162 | – | – | 162 |
| Terrance McGuire Director | Apr 1, 2019 | Award | +6,911 | – | – | 6,911 |
| Peter M. Hecht Chief Executive Officer, Director | Apr 1, 2019 | Award | +485 | – | – | 485 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 2 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Korsana Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 26,971 shares on Sep 9, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Michael J. Higgins Director | Oct 22, 2026 | 1,107 | $35.42K | Oct 22, 2026 | Restricted Stock |
| Errol B De Souza Director | Sep 23, 2026 | 4,903 | $171.56K | Sep 23, 2026 | Restricted Stock |
| Errol B De Souza Director | Sep 22, 2026 | 100 | $3.50K | Sep 22, 2026 | Restricted Stock |
| Errol B De Souza Director | Sep 18, 2026 | 2,139 | $74.84K | Sep 18, 2026 | Restricted Stock |
See a number that looks wrong?